

Application Serial No. 10/815,168
Amendment dated April 13, 2005
Reply to Office Action of January 14, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (currently amended) A synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of the plants *Gentiana kurroo* efat a concentration ranging between 2-5 wt %, *Murraya koenigii* efat a concentration ranging between 8-15 wt %, *Allium sativum* efat a concentration ranging between 2-4 wt %, *Zingiber officinalis* efat a concentration ranging between 2-5 wt %, *Amorrrhophallus campanalatus* efat a concentration ranging between 1-10 wt %, and one or more pharmaceutically acceptable additive(s).
2. (original) The composition as claimed in claim 1, wherein the additives are selected from a group comprising binders, diluents, and lubricants.
3. (original) The composition as claimed in claim 2, wherein the binder is selected from a group comprising starch, starch paste, gum acacia, and carboxy methylcellulose.
4. (original) The composition as claimed in claim 2, wherein the diluent is lactose.
5. (original) The composition as claimed in claim 2, wherein the lubricant is selected from a group comprising starch, and lactose.
6. (original) The composition as claimed in claim 1, wherein the composition is administered orally.
7. (original) The composition as claimed in claim 1, wherein the extracts are obtained from plant parts selected from a group comprising leaf, rhizome, and aerial parts.

Application Serial No. 10/815,168
Amendment dated April 13, 2005
Reply to Office Action of January 14, 2005

8. (original) The composition as claimed in claim 1, wherein the extract of plant *Gentiana Kurroo* is a root extract.
9. (original) The composition as claimed in claim 1, wherein the composition is in lyophilized form.
10. (original) The composition as claimed in claim 1, wherein the composition reduces body weight, total serum cholesterol level, phospholipids and triglycerides.
11. (original) The composition as claimed in claim 1, wherein the composition is useful in treating obesity, and atherosclerosis.
12. (original) The composition as claimed in claim 1, wherein the composition helps in keep slim.
13. (currently amended) A process for the preparation of a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of the plants *Gentiana kurroo* efat a concentration ranging between 2-5 wt %, *Murraya koenigii* efat a concentration ranging between 8-15 wt %, *Allium sativum* efat a concentration ranging between 2-4 wt %, *Zingiber officinalis* efat a concentration ranging between 2-5 wt %, *Amorrrhophallus campanalatus* efat a concentration ranging between 1-10 wt %, and one or more pharmaceutically acceptable additive(s), said process comprising steps of:
 - a. drying leaves, rhizome and/or aerial parts of the aforementioned plants in shade,
 - b. powdering the dried plant material to a coarse powder,
 - c. extracting the powdered dried plant material with 35 to 55% alcohol in the ratio of 1:7 to 1:17 at room temperature for time duration ranging between 3-8 days,
 - d. concentrating the extract at under reduced pressure at temperature ranging between 35-65 °C,
 - e. lyophilizing the concentrated extract for complete removal of solvent, and
 - f. blending the lyophilized extract with additives to obtain the composition.

Application Serial No. 10/815,168
Amendment dated April 13, 2005
Reply to Office Action of January 14, 2005

14. (original) The process as claimed in claim 13, wherein the alcohol is ethanol.
15. (original) The process as claimed in claim 13, wherein the room temperature is ranging between 25 to 35°C.
16. (original) The process as claimed in claim 13, wherein the additives constitutes the remaining wt % of the composition after addition of herbal extracts.
17. (original) The process as claimed in claim 13, wherein the extract of plant *Gentiana kurroo* is a root extract.
18. (original) The process as claimed in claim 13, wherein the additives are selected from a group comprising binders, diluents, and lubricants.
19. (original) The process as claimed in claim 18, wherein the binder is selected from a group comprising starch, starch paste, gum acacia, and carboxy methylcellulose.
20. (original) The process as claimed in claim 18, wherein the diluent is lactose.
21. (original) The process as claimed in claim 18, wherein the lubricant is selected from a group comprising starch, and lactose.
22. (currently amended) A method for treating hyperlipidemia, comprising administering to a subject in need thereof~~Use of~~ a synergistic pharmaceutical composition comprising extracts of plant *Gentiana kurroo* of concentration ranging between 2-5 wt. %, *Murraya koenigii* of the ~~plants~~ *Gentiana kurroo* ~~efat~~ a concentration ranging between 2-5 wt. %, *Murraya koenigii* ~~efat~~ a concentration ranging between 8-15 wt %, *Allium sativum* ~~efat~~ a concentration ranging between 2-4 wt %, *Zingiber officinalis* ~~efat~~ a concentration ranging between 2-5 wt %, *Amorrhophallus campanalatus* ~~efat~~ a concentration ranging between 1-10 wt %, and one or more

Application Serial No. 10/815,168
Amendment dated April 13, 2005
Reply to Office Action of January 14, 2005

pharmaceutically acceptable additive(s) to a subject in need thereof for treating hyperlipidemia, by administering pharmaceutically effective amount of the said composition.

23. (currently amended) The method of use as claimed in claim 22, wherein the extract of plant *Gentiana kurroo* is a root extract.

24. (currently amended) The method of use as claimed in claim 22, wherein the additives are selected from a group comprising binders, diluents, and lubricants.

25. (currently amended) The method of use as claimed in claim 24, wherein the binder is selected from a group comprising starch, starch paste, gum acacia, and carboxy methylcellulose.

26. (currently amended) The method of use as claimed in claim 24, wherein the diluent is lactose.

27. (currently amended) The method of use as claimed in claim 24, wherein the lubricant is selected from a group comprising starch, and lactose.

28. (currently amended) The method of use as claimed in claim 22, wherein the method decreases hyperlipidemia by about 20-30%.

29. (currently amended) ~~The use as claimed in claim 22~~ A method for treating atherosclerosis, comprising administering to a subject in need thereof the wherein the composition is useful in the treatment of atherosclerosis claim 1.

30. (currently amended) ~~The use as claimed in claim 22~~ A method for treating obesity, comprising administering to a subject in need thereof the wherein the composition is useful in the treatment of obesity claim 1.

Application Serial No. 10/815,168
Amendment dated April 13, 2005
Reply to Office Action of January 14, 2005

31. (currently amended) The method of use as claimed in claim 22, wherein the method reduces body weight, total serum cholesterol level, phospholipids and triglycerides by about 18-25%.
32. (currently amended) The method of use as claimed in claim 22, wherein the method helps in maintaining slimness.
33. (currently amended) The method of use as claimed in claim 22, wherein the subject is an animal.
34. (currently amended) The method of use as claimed in claim 22, wherein the subject is a human.